Best Practice & Research in Clinical Rheumatology最新文献_第5页

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.101972

Guangju Zhai, Jingyi Huang

引用次数: 0

Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice 幼年皮肌炎的个性化医疗：从疾病机制的新见解到临床实践的改变。

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101976

Saskia R. Veldkamp , Femke van Wijk , Annet van Royen-Kerkhof , Marc HA. Jansen

{"title":"Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice","authors":"Saskia R. Veldkamp , Femke van Wijk , Annet van Royen-Kerkhof , Marc HA. Jansen","doi":"10.1016/j.berh.2024.101976","DOIUrl":"10.1016/j.berh.2024.101976","url":null,"abstract":"<div><div>Juvenile dermatomyositis is characterized by childhood-onset chronic inflammation of the muscles and skin, with potential involvement of other organs. Patients are at risk for long-term morbidity due to insufficient disease control and steroid-related toxicity. Personalised treatment is challenged by a lack of validated tools that can reliably predict treatment response and monitor ongoing (subclinical) inflammation, and by a lack of evidence regarding the best choice of medication for individual patients. A better understanding of the involved disease mechanisms could reveal potential biomarkers and novel therapeutic targets. In this review, we highlight the most relevant immune and non-immune mechanisms, elucidating the effects of interferon overexpression on tissue alongside the interplay between the interferon signature, mitochondrial function, and immune cells. We review mechanism-based biomarkers that are promising for clinical implementation, and the latest advances in targeted therapy development. Finally, we discuss key steps needed for translating these discoveries into clinical practice.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 3","pages":"Article 101976"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of JIA associated uveitis JIA相关葡萄膜炎的治疗

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101979

Ilaria Maccora , Gabriele Simonini , Catherine M. Guly , Athimalaipet V. Ramanan

{"title":"Management of JIA associated uveitis","authors":"Ilaria Maccora , Gabriele Simonini , Catherine M. Guly , Athimalaipet V. Ramanan","doi":"10.1016/j.berh.2024.101979","DOIUrl":"10.1016/j.berh.2024.101979","url":null,"abstract":"<div><div><span><span>Juvenile Idiopathic Arthritis<span> (JIA) is the most common chronic rheumatic disease<span> in childhood, and is associated with uveitis<span> in up to 20–25% of cases. Typically, the uveitis is chronic, asymptomatic, non-granulomatous and anterior. For this reason, screening for uveitis is recommended to identify uveitis early and allow treatment to prevent sight-threatening complications. The management of JIA associated uveitis requires a multidisciplinary approach and a close collaboration between </span></span></span></span>paediatric rheumatologist and ophthalmologist. Starting the appropriate treatment to control uveitis activity and prevent ocular complications is crucial. Current international recommendations advise a step-wise approach, starting with </span>methotrexate<span> and moving on to adalimumab<span><span> if methotrexate alone is not sufficient to control the disease. If the uveitis remains active despite standard treatment other therapeutic options may be considered including anti-IL6 or other anti-TNF agents such as </span>infliximab, although the evidence for these agents is limited.</span></span></div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 3","pages":"Article 101979"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Capillaroscopy in the daily clinic of the pediatric rheumatologist 儿科风湿病医生日常门诊中的毛细血管镜检查。

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101978

D. Schonenberg-Meinema , M. Cutolo , V. Smith

引用次数: 0

Antiphospholipid syndrome in children 儿童抗磷脂综合征

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101986

Mojca Zajc Avramovic , Tadej Avcin

{"title":"Antiphospholipid syndrome in children","authors":"Mojca Zajc Avramovic , Tadej Avcin","doi":"10.1016/j.berh.2024.101986","DOIUrl":"10.1016/j.berh.2024.101986","url":null,"abstract":"<div><div>Antiphospholipid syndrome (APS) in children is a rare disease associated with significant morbidity and mortality. In comparison with APS in adults, pediatric APS has a more severe presentation with frequent recurrences of thrombotic events and a higher probability of life-threatening catastrophic APS. Nonthrombotic manifestations are also more common in the pediatric age group and can precede thrombosis. New classification criteria have been introduced recently and have not yet been assessed in pediatric patients with APS. In addition to anticoagulation drugs, other novel therapies have emerged including the use of B cell and complement inhibitors, especially in catastrophic APS. The purpose of this review is to provide a broad overview of aPL-related clinical manifestations in pediatric patients based on the analysis of published cohorts and data from the international pediatric APS registry. We also aim to illustrate APS in infants caused by transplacentally transferred maternal aPL, which is very rarely associated with acute thrombotic events in the perinatal period and more frequently with long-term neurodevelopmental abnormalities.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 3","pages":"Article 101986"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interferonopathies: From concept to clinical practice 干扰素病：从概念到临床实践。

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101975

Leonardo Oliveira Mendonça , Marie-Louise Frémond

引用次数: 0

A lifelong journey: Long-term perspectives on Juvenile Idiopathic Arthritis 终生之旅：青少年特发性关节炎的长期展望。

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101984

Filipa Oliveira Ramos , Carolina Zinterl , João Eurico Fonseca

{"title":"A lifelong journey: Long-term perspectives on Juvenile Idiopathic Arthritis","authors":"Filipa Oliveira Ramos , Carolina Zinterl , João Eurico Fonseca","doi":"10.1016/j.berh.2024.101984","DOIUrl":"10.1016/j.berh.2024.101984","url":null,"abstract":"<div><div>Juvenile Idiopathic Arthritis (JIA) represents a diverse group of chronic inflammatory conditions that begin in childhood or adolescence and continue into adulthood, with varying severity and outcomes.</div><div>This review discusses the complexities of transitioning JIA patients emphasizing that inadequate transition from pediatric to adult care leads to loss of follow-up, treatment discontinuation, and increased disease activity. Furthermore, challenges in disease classification hinder continuity of care across lifespan.</div><div>It is also pointed out that predicting long-term outcomes in JIA remains complex due to heterogeneity and evolving phenotypes. Factors such as disease category, joint involvement, and treatment influence disease activity, functional disability, and quality of life. Despite advancements in treatment strategies, a substantial proportion of patients experience long-term disability and joint damage.</div><div>Finally, it is underscored that optimising long-term outcomes in adults with JIA requires a multifaceted approach encompassing structured transition processes, personalised treatment strategies, and comprehensive management of comorbidities. Further research is needed to refine predictive models, enhance disease monitoring tools, and understand the complex interplay between disease activity, treatment response, and long-term outcomes.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 3","pages":"Article 101984"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The inequity of global healthcare in pediatric rheumatology 儿科风湿病学全球医疗保健的不平等。

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101983

Soamarat Vilaiyuk , Djohra Hadef , Wafa Hamdi , Chris Scott , Waheba Slamang , Helen E. Foster , Laura B. Lewandowski

{"title":"The inequity of global healthcare in pediatric rheumatology","authors":"Soamarat Vilaiyuk , Djohra Hadef , Wafa Hamdi , Chris Scott , Waheba Slamang , Helen E. Foster , Laura B. Lewandowski","doi":"10.1016/j.berh.2024.101983","DOIUrl":"10.1016/j.berh.2024.101983","url":null,"abstract":"<div><div>In pediatric rheumatology, global health inequity relates to the uneven distribution of healthcare resources, accessibility, and health outcomes among children with rheumatic conditions across various countries, regions, and socioeconomic groups. This inequity can manifest in various ways. This review article provides an overview of common rheumatic diseases, such as juvenile idiopathic arthritis and systemic lupus erythematosus, which significantly contribute to and are affected by disparities in global healthcare.</div><div>Subsequently, we delve into the inequalities in accessing patient care, encompassing issues related to diagnosis and treatment. Additionally, we address challenges in educational advancement and identify research gaps within the field of pediatric rheumatology. We also reveal successful global collaborations, such as a Global Task Force for Pediatric Musculoskeletal Health and special working groups among international organizations, aimed at bridging the disparities gap. Through these efforts, we try to enhance understanding, cooperation, and resource allocation to ensure equal access to quality care worldwide for children with rheumatic conditions. Futhermore, we present a case study from Thailand, highlighting their successful initiatives in developing pediatric rheumatology within their healthcare system.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 3","pages":"Article 101983"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to treat monogenic SLE? 如何治疗单基因系统性红斑狼疮？

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101962

引用次数: 0

38.3 Primary Immunodeficiencies: When is it not just “JIA” 38.3 原发性免疫缺陷：何时不仅仅是 "JIA"。

IF 4.5 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-09-01 DOI: 10.1016/j.berh.2024.101960

引用次数: 0